{ "FullStudy":{ "Rank":217676, "Study":{ "ProtocolSection":{ "IdentificationModule":{ "NCTId":"NCT01518283", "OrgStudyIdInfo":{ "OrgStudyId":"CABASEM-SOGUG" }, "Organization":{ "OrgFullName":"Spanish Oncology Genito-Urinary Group", "OrgClass":"OTHER" }, "BriefTitle":"Study of Weekly Cabazitaxel for Advanced Prostate Cancer", "OfficialTitle":"Phase II Study of Weekly Cabazitaxel for Advanced Prostate Cancer in \"Unfit\" Hormone-Refractory Patients Previously Treated With Docetaxel" }, "StatusModule":{ "StatusVerifiedDate":"November 2015", "OverallStatus":"Completed", "ExpandedAccessInfo":{ "HasExpandedAccess":"No" }, "StartDateStruct":{ "StartDate":"May 2012" }, "PrimaryCompletionDateStruct":{ "PrimaryCompletionDate":"June 2016", "PrimaryCompletionDateType":"Actual" }, "CompletionDateStruct":{ "CompletionDate":"July 2016", "CompletionDateType":"Actual" }, "StudyFirstSubmitDate":"January 17, 2012", "StudyFirstSubmitQCDate":"January 21, 2012", "StudyFirstPostDateStruct":{ "StudyFirstPostDate":"January 25, 2012", "StudyFirstPostDateType":"Estimate" }, "LastUpdateSubmitDate":"June 29, 2017", "LastUpdatePostDateStruct":{ "LastUpdatePostDate":"July 2, 2017", "LastUpdatePostDateType":"Actual" } }, "SponsorCollaboratorsModule":{ "ResponsibleParty":{ "ResponsiblePartyType":"Sponsor" }, "LeadSponsor":{ "LeadSponsorName":"Spanish Oncology Genito-Urinary Group", "LeadSponsorClass":"OTHER" } }, "OversightModule":{ "OversightHasDMC":"No" }, "DescriptionModule":{ "BriefSummary":"This is a multicenter open label non randomized phase II clinical trial of Weekly Cabazitaxel for Advanced Prostate Cancer in Hormone-Refractory Patients Previously Treated with Docetaxel.\n\nThe purpose of this study is to evaluate the activity of the weekly administration of cabazitaxel as time to progression by PSA at week 12.", "DetailedDescription":"The efficacy of three-weekly cabazitaxel is accompanied by an appreciable rate of serious side effects and toxic deaths. The toxicity rates observed, including grade III-IV neutropenia, febrile neutropenia and diarrhea, could be an obstacle to the use and management of a drug that, on the other hand, has demonstrated great activity. In the treatment of patients with prostate cancer, who have a larger number of morbidities than patients with breast cancer, we assume the risk that in the transition from clinical trial to clinical practice the drug will not be used much because of the risk of side effects, cost, the discomfort derived from the routine use of G-CSF and the lack of patient compliance with this type of regimens.\n\nRates of neuropathy, nail and conjunctive toxicity with this new taxane are not relevant, which suggests that weekly administration will not produce relevant toxicity problems. Weekly administration of other taxanes improved hematologic tolerance along with a better therapeutic range in some cases, increasing the dose intensity and activity without increasing the associated toxicity.\n\nPhase I study has been reported studying weekly administration of cabazitaxel, recommended dose is 10 mg/m2, administered on days 1, 8, 15 and 22 every 5 weeks in a 1-hour infusion, being diarrhea the dose-limiting toxicity observed in this study.\n\nGiven the pharmacokinetic characteristics of this taxane and its activity and toxicity profile, cabazitaxel might be a good candidate for studying in a weekly administration regimen in patients with prostate cancer with a greater risk of toxicity associated with treatment every 3 weeks, such as patients who have received previous pelvic radiation therapy that affects more than 25% of the bone marrow reserve, patients over 75 years with a worse performance status (ECOG 2) or who have already experienced important hematologic toxicity in the previous treatment with docetaxel." }, "ConditionsModule":{ "ConditionList":{ "Condition":[ "Hormone Refractory Prostate Cancer" ] }, "KeywordList":{ "Keyword":[ "Weekly cabazitaxel.", "Advanced Hormone-refractory prostate Cancer.", "Unfit patients." ] } }, "DesignModule":{ "StudyType":"Interventional", "PhaseList":{ "Phase":[ "Phase 2" ] }, "DesignInfo":{ "DesignInterventionModel":"Single Group Assignment", "DesignPrimaryPurpose":"Treatment", "DesignMaskingInfo":{ "DesignMasking":"None (Open Label)" } }, "EnrollmentInfo":{ "EnrollmentCount":"74", "EnrollmentType":"Actual" } }, "ArmsInterventionsModule":{ "ArmGroupList":{ "ArmGroup":[ { "ArmGroupLabel":"Cabazitaxel", "ArmGroupType":"Experimental", "ArmGroupDescription":"Drug: Cabazitaxel 10 mg/m2", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: Cabazitaxel 10 mg/m2" ] } } ] }, "InterventionList":{ "Intervention":[ { "InterventionType":"Drug", "InterventionName":"Cabazitaxel 10 mg/m2", "InterventionDescription":"Cabazitaxel 10 mg/m2 in a 1-hour infusion on days 1, 8, 15 and 22 of 5-week cycles.", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "Cabazitaxel" ] }, "InterventionOtherNameList":{ "InterventionOtherName":[ "Jevtana" ] } } ] } }, "OutcomesModule":{ "PrimaryOutcomeList":{ "PrimaryOutcome":[ { "PrimaryOutcomeMeasure":"Time to progression by PSA at week 12, according to the PCCTWG II criteria.", "PrimaryOutcomeDescription":"Time to progression by PSA at week 12. PSA progression defined as an increase of ≥25% over nadir PSA concentration provided that the increase in the absolute PSA value was ≥5 μg/L for men with no PSA response, or ≥50% over nadir for PSA responders and PSA responders defined as a reduction in serum PSA concentration of ≥50% in patients with a baseline value of ≥20 μg/L.", "PrimaryOutcomeTimeFrame":"12 weeks" } ] }, "SecondaryOutcomeList":{ "SecondaryOutcome":[ { "SecondaryOutcomeMeasure":"time to PSA progression", "SecondaryOutcomeDescription":"Time to PSA progression, according to the PCCTWG II criteria, defined as the time between enrolment and the first date of PSA progression.", "SecondaryOutcomeTimeFrame":"Patients will be followed until PSA progression, an expected average of 6 months" },{ "SecondaryOutcomeMeasure":"biochemical response rate", "SecondaryOutcomeDescription":"Biochemical response by PSA determination defined as the percentage of patients with 30%,50% and 80% reduction respect to baseline in patients with a baseline value >=20 mcg/L confirmed by a repeat PSA measurement after at least 3 weeks.", "SecondaryOutcomeTimeFrame":"Patients will be followed until end of treatment, an expected average of 6 months" },{ "SecondaryOutcomeMeasure":"Objective response rate", "SecondaryOutcomeDescription":"Proportion of patients with an objective tumoral response according to modified RECIST criteria", "SecondaryOutcomeTimeFrame":"Patients will be followed until end of treatment, an expected average of 6 months" },{ "SecondaryOutcomeMeasure":"Overall survival", "SecondaryOutcomeDescription":"Overall survival is calculated since the date of patient study enrolment till death.", "SecondaryOutcomeTimeFrame":"Patients will be followed until death, an expected average of 18 months" },{ "SecondaryOutcomeMeasure":"Evaluate the safety and tolerability profile of cabazitaxel.", "SecondaryOutcomeDescription":"All adverse events will be graded according to National Cancer Institute Common Terminology Criteria for adverse events (version 4.03).\n\nAdverse events, biochemistry, hematology, vital signs and electrocardiograms will be monitored throughout the study.", "SecondaryOutcomeTimeFrame":"6 months (during treatment)" },{ "SecondaryOutcomeMeasure":"Pain response", "SecondaryOutcomeDescription":"Determine the pain response in patients with stable pain at baseline by means of the McGill-Melzack MPQ-sf questionnaire, defined as ≥ 2 points with respect to baseline on the PPI scale without increase in the analgesic scale, or with a decrease of ≥ 50% in the use of analgesics without an increase in pain that is maintained for more than 3 weeks.", "SecondaryOutcomeTimeFrame":"Until end of treatment, an expected average of 6 months" },{ "SecondaryOutcomeMeasure":"Correlation between presence-absence of baseline pain with overall survival, time to progression and PSA response rate.", "SecondaryOutcomeTimeFrame":"Until death, an expected average of 18 months" },{ "SecondaryOutcomeMeasure":"Correlation of the Charlson co-morbidity index and ADL/IADL dependency indexes with survival and toxicity", "SecondaryOutcomeTimeFrame":"Until death, an expected average of 18 months" },{ "SecondaryOutcomeMeasure":"Assessment and quantification of Circulating Tumour Cells and level correlation between the beginning of treatment and their variation through treatment with time to progression and overall survival", "SecondaryOutcomeTimeFrame":"Until death, an expected average of 18 months" } ] } }, "EligibilityModule":{ "EligibilityCriteria":"Inclusion Criteria:\n\nPatients who have given written informed consent.\nAge ≥ 18 years.\nECOG 0-2.\nPatients with a histologic or cytologic diagnosis of advanced prostate cancer (any Gleason grade).\nPrevious and ongoing castration by orchiectomy or LHRH agonists. Antiandrogen must be discontinued prior to study start.\nDisease progression, clinically or radiologically documented, during or after treatment with docetaxel, with a minimum cumulative dose of 225 mg/m2.\n\n\"Unfit\" patients defined as patients who satisfy at least one of the following criteria:\n\nECOG 2\nDose reduction due to febrile neutropenia during the previous treatment with docetaxel\nRadiation therapy affecting more than 25% of bone marrow reserve\n\nDocumented metastatic disease and progressing after docetaxel treatment. Progression criteria is considered any of the following three or more than one at once:\n\nProgressive elevation of PSA measured in three successive determinations one week difference between them at least;\nShould be considered progression of measurable disease by RECIST criteria;\nBone progression as evidenced by the appearance of two or more new lesions on bone scan.\nPatients who have received a maximum of one prior chemotherapy for metastatic disease.\nPrior anticancer therapy should have been interrupted 28 days before the start of study treatment (the patient may have continued treatment with prednisone 5 mg bid.\n\nAdequate blood, liver and kidney function:\n\nHemoglobin > 9.0 g/dl\nANC > 1.5 x 10*9/L\nPlatelets > 100 x 10*9/L\nAST/SGOT and ALT/SGPT < 2.5 x ULN\nBilirubin < 1.0 x ULN\nCreatinine <1.5 mg/dL x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance <60 mL/min should be excluded (see Annex 7 for formula)\nAdequate baseline cardiac function (LVEF ≥ 50%).\nLife expectancy ≥ 12 weeks.\nPatients must agree to use an effective contraceptive method during treatment with the study drug and up to 1 month after ending the treatment.\n\nExclusion Criteria:\n\nPatients who received radiation therapy that exceeded 40% of the bone marrow reserve or that ended within the last 3 weeks prior to inclusion.\nIf being treated with radiation therapy, should be completed before the three weeks prior to initiation of treatment research.\nPrevious treatment with two or more chemotherapy regimens for metastatic disease. A new line of treatment is also when a patient receives again docetaxel after clinical, radiological or PSA progression to a prior regimen with docetaxel.\nPrevious treatment with chemotherapy or surgery in the last 4 weeks.\nPeripheral neuropathy or stomatitis ≥ 2 (National Cancer Institute Common Terminology Criteria - NCI CTCAE vs. 4.03).\nAny other type of cancer in the last 5 years, except for basal cell skin carcinoma.\nCerebral or leptomeningeal metastasis.\nMyocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass, congestive heart failure (NYHA class III or IV), stroke or transitory ischemic episodes.\nPatients who present any severe or uncontrolled medical condition (including uncontrolled diabetes mellitus) or any other condition that may affect the patient's participation and study compliance.\nPrevious treatment with cabazitaxel.\nKnown hypersensitivity (≥ grade 3)to cabazitaxel, polysorbate 80, prednisone or prednisolone, or docetaxel or paclitaxel.\nKnown history of active infection that requires systemic antibiotic or antifungal treatment.\nPatients who are receiving or expect to receive treatment with strong inhibitors or strong inducers of cytochrome CYP450 3A4/5 (a one week wash-out period is necessary for patients who are already on these treatments) (see Annexes 5 and 6).\nPatients being treated with any investigational product.", "HealthyVolunteers":"No", "Gender":"Male", "MinimumAge":"18 Years", "StdAgeList":{ "StdAge":[ "Adult", "Older Adult" ] } }, "ContactsLocationsModule":{ "OverallOfficialList":{ "OverallOfficial":[ { "OverallOfficialName":"Miguel A Climent, MD", "OverallOfficialAffiliation":"FUNDACIÓN INSTITUTO VALENCIANO DE ONCOLOGÍA, Servicio de Oncología Médica, Profesor Beltrán Báguena, 11, 8 y 19, Valencia, 46009", "OverallOfficialRole":"Principal Investigator" } ] }, "LocationList":{ "Location":[ { "LocationFacility":"Complejo Hospitalario Universitario de Santiago", "LocationCity":"Santiago de Compostela", "LocationState":"A Coruña", "LocationZip":"15706", "LocationCountry":"Spain" },{ "LocationFacility":"Institut Català D'Oncologia L'Hospitalet (Ico)", "LocationCity":"L'Hospitalet de Llobregat", "LocationState":"Barcelona", "LocationZip":"08908", "LocationCountry":"Spain" },{ "LocationFacility":"Hospital de Sant Joan de Déu", "LocationCity":"Manresa", "LocationState":"Barcelona", "LocationZip":"08243", "LocationCountry":"Spain" },{ "LocationFacility":"Hospital Universitario Fundación Alcorcón", "LocationCity":"Alcorcón", "LocationState":"Madrid", "LocationZip":"28922", "LocationCountry":"Spain" },{ "LocationFacility":"Hospital Clinic I Provincial de Barcelona", "LocationCity":"Barcelona", "LocationZip":"08036", "LocationCountry":"Spain" },{ "LocationFacility":"Hospital General Universitario Gregorio Marañón", "LocationCity":"Madrid", "LocationZip":"28007", "LocationCountry":"Spain" },{ "LocationFacility":"Hospital Universitario 12 de Octubre", "LocationCity":"Madrid", "LocationZip":"28041", "LocationCountry":"Spain" },{ "LocationFacility":"Complejo Hospitalario de Ourense", "LocationCity":"Ourense", "LocationZip":"32005", "LocationCountry":"Spain" },{ "LocationFacility":"Hospital Virgen Del Rocío", "LocationCity":"Sevilla", "LocationZip":"41013", "LocationCountry":"Spain" },{ "LocationFacility":"Hospital Nuestra Señora de Valme", "LocationCity":"Sevilla", "LocationZip":"41014", "LocationCountry":"Spain" },{ "LocationFacility":"Fundación Instituto Valenciano de Oncología", "LocationCity":"Valencia", "LocationZip":"46009", "LocationCountry":"Spain" },{ "LocationFacility":"Consorcio Hospital General Universitario de Valencia", "LocationCity":"Valencia", "LocationZip":"46014", "LocationCountry":"Spain" } ] } } }, "DerivedSection":{ "MiscInfoModule":{ "VersionHolder":"April 22, 2020" }, "ConditionBrowseModule":{ "ConditionMeshList":{ "ConditionMesh":[ { "ConditionMeshId":"D000011471", "ConditionMeshTerm":"Prostatic Neoplasms" } ] }, "ConditionAncestorList":{ "ConditionAncestor":[ { "ConditionAncestorId":"D000005834", "ConditionAncestorTerm":"Genital Neoplasms, Male" },{ "ConditionAncestorId":"D000014565", "ConditionAncestorTerm":"Urogenital Neoplasms" },{ "ConditionAncestorId":"D000009371", "ConditionAncestorTerm":"Neoplasms by Site" },{ "ConditionAncestorId":"D000009369", "ConditionAncestorTerm":"Neoplasms" },{ "ConditionAncestorId":"D000005832", "ConditionAncestorTerm":"Genital Diseases, Male" },{ "ConditionAncestorId":"D000011469", "ConditionAncestorTerm":"Prostatic Diseases" } ] }, "ConditionBrowseLeafList":{ "ConditionBrowseLeaf":[ { "ConditionBrowseLeafId":"M12918", "ConditionBrowseLeafName":"Prostatic Neoplasms", "ConditionBrowseLeafAsFound":"Prostate Cancer", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M7529", "ConditionBrowseLeafName":"Genital Neoplasms, Male", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M15898", "ConditionBrowseLeafName":"Urogenital Neoplasms", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M7527", "ConditionBrowseLeafName":"Genital Diseases, Male", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M12916", "ConditionBrowseLeafName":"Prostatic Diseases", "ConditionBrowseLeafRelevance":"low" } ] }, "ConditionBrowseBranchList":{ "ConditionBrowseBranch":[ { "ConditionBrowseBranchAbbrev":"BC04", "ConditionBrowseBranchName":"Cancers and Other Neoplasms" },{ "ConditionBrowseBranchAbbrev":"BXS", "ConditionBrowseBranchName":"Urinary Tract, Sexual Organs, and Pregnancy Conditions" },{ "ConditionBrowseBranchAbbrev":"All", "ConditionBrowseBranchName":"All Conditions" } ] } } } } } }